Comparing EVCO and EVOO

Comparing Acute Effects of Extra Virgin Coconut Oil and Extra Virgin Olive Oil Consumption on Appetite and Food Intake in Normal Weight and Obese Male Subjects

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04738929

Enrollment

Registered

2021-02-04

Start date

2019-01-03

Completion date

2019-06-03

Last updated

2021-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Appetitive Behavior, Obesity

Keywords

Extra virgin coconut oil; medium chain fatty acids; extra virgin olive oil; obesity; peptide YY; resting metabolic rate.

Brief summary

The aim of this study is to compare acute effects of consuming extra virgin coconut oil (EVCO) as a source of medium chain fatty acids and extra virgin olive oil (EVOO) as a source of long chain fatty acids in normal weight and obese subjects.

Detailed description

Twenty male subjects (10 normal weight; 10 obese) consumed breakfast meals containing skimmed milk, fat-free white cheese, bread and EVCO (25 g) or EVOO (25 g). Visual analog scale evaluations, resting metabolic rate measurements and selected blood parameters analysis (glucose, triglyceride, insulin and plasma peptide YY) were performed before and after the test breakfast meals. In addition, energy intakes were evaluated by ad libitum lunch meal at 180 min.

Interventions

OTHERExtra virgin coconut oil or extra virgin olive oil

Subjects consumed standard breakfast meals containing extra virgin coconut oil or extra virgin olive oil

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

19 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Metabolically healthy * Aged 19-40 years * Normal weight (BMI=18.5-24.9 kg/m²) and obese men (BMI=30-34.99 kg/m²)

Exclusion criteria

* smoking, * alcohol consumption, * weight gain/loss recently (\> %5, in three months), * any genetic and metabolic diseases, * any food allergy/intolerance, * any medication, * restrained eating habits.

Design outcomes

Primary

Measure	Time frame	Description
Energy expenditure change	0, 60, 120, 180 minutes	kcal
Subjective appetite feelings change	0, 30, 60, 120, 180 minutes	visual analogue scales rating (0-10 cm)
glucose change	0, 30, 60, 120, 180 minutes	mg/dl
insulin change	0, 30, 60, 120, 180 minutes	mU/L
peptide YY change	0, 30, 60, 120, 180 minutes	pg/dl
triglycerides change	0, 30, 60, 120, 180 minutes	mg/dl
Ad libitum energy intake	180 minute	kcal

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026